On August 26-27, the "2023 First (Beijing) Cell Pharmaceutical Industry Development Conference" sponsored by the Regenerative Medicine Professional Committee of China Medical Biotechnology Association and the Xidei New Drug Talent Club, co-organized by Beijing Huasheng Biotechnology Co., Ltd. was held in Beijing Quintai Hotel, inviting experts and scholars from the industry, regulatory circles, clinical circles, etc. Ask about the future of cutting-edge technologies in global cell science and translational medicine, and promote local innovation landing and breakthrough.

With the theme of "Cell smart drugs, future therapies", this conference has one main forum and five thematic sub-forums, covering different subdivisions such as stem cell drug development, gene therapy drug development, immune cells, exosomes and so on. Strive to build a cellular pharmaceutical ecosystem to promote in-depth exchanges and cooperation.

At the Immune Cell Forum, chief scientist Professor Wang Jianxun delivered a speech on the theme of "Selection of viral vectors in the industrial production of cell therapy Drugs", discussing with experts and scholars the updating of technology and industry trends. Professor Wang Jianxun said that cellular biomedicine is the forefront of biotechnology and a key technology related to people's health, which has shown great application potential in the treatment of malignant tumors, autoimmune diseases, metabolic diseases and other fields.

Professor Wang Jianxun pointed out that the viral vector is a key raw material for cell therapy, and it is a good tool for gene delivery and has irreplaceable advantages. The most widely used in cell therapy are retroviral vectors and lentiviral vectors. For the large domestic cancer population, retroviral vector technology has shown advantages in industrial production capacity and production cost, and has received much attention and concern in the global research pipeline and the application of listed cellular drugs. Shenzhen Cell Valley Biomedicine Co., Ltd. is the only CRO/CDMO one-stop outsourcing service provider in China that has mastered industrial retrovirus vector technology (PackRV-SE and other systems). Industrial production of GMP-grade retrovirus (RVV), lentivirus (LVV) and other viral vector production pipelines and CAR-T, CAR-NK, TCR-T and other cell production pipelines can effectively solve the "jam neck" dilemma of key raw material production capacity and cost of cell therapy, so that the leading technology of the cell industry can actually benefit more patients.

In this exhibition, Shenzhen Cell Valley received much attention, showing visitors from all walks of life its unique technical advantages and corporate style, laying a solid foundation for future exchanges and cooperation.